New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
13:30 EDTDYAX, BCRXBioCryst data has favorable read through for Dyax, says Jefferies
After Biocryst (BCRX) reported positive data from a trial evaluating BCX4161 in hereditary angioedema, Jefferies said the study results point to higher odds for the success of Dyax's (DYAX) DX-2930, which has a similar pathway and is being developed as a prophylactic treatment for HAE. The firm maintains its Buy rating and $13.00 price target on Dyax.
News For DYAX;BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
15:17 EDTBCRXBioCryst management to meet with JPMorgan
Subscribe for More Information
May 13, 2015
07:00 EDTBCRXBioCryst initiates Phase 1 clinical trial of angioedema candidate
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use